Know Cancer

forgot password

Phase IIa Study of Metastatic Breast Cancer

Phase 2
20 Years
80 Years
Not Enrolling
Metastatic Breast Cancer

Thank you

Trial Information

Phase IIa Study of Metastatic Breast Cancer

The test article is extracted from many natural herbals, in which most or their components
have been shown to have anti-tumor activity. A study in 2004 showed the test article could
have strong immunomodulatory effect on the antigen-stimulated proliferation response (PR) of
peripheral blood mononuclear cells (PBMC) and T-cells from recurrent aphthous ulcerations
(RAU) patients and suggested that it might be a potential immunoceutical agent for treatment
of RAU. Subsequent study in 2005 also suggested the test article as a potential
immunoceutical agent for treatment of RAU because the result showed it could modulate the
antigen-stimulated cytokine production by T-cells isolated from RAU patients. Another study
in 2005 showed the test article also had a broad-range tumor killing function and provided a
molecular basis underlying therapeutic activity. It was also suggested in this study will
could be a potential and promising cancer therapeutic or preventive agent.

The aim of this current study is to explore the safety and efficacy of the investigational
product with 20 ml, 3 times per day (daily dose: 60 ml) for a total of 24 weeks in the
patients with metastatic breast cancer refractory to conventional treatment modalities.

Inclusion Criteria:

- Confirmed breast cancer with clinical evidence.

- Life expectancy of at least 4 weeks.

Exclusion Criteria:

- Any Uncontrolled infection.

- Lupus erythematosus.

- Malignant tumor.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:


Outcome Time Frame:

6 months measure

Safety Issue:


Principal Investigator

King-Jen Chang, M.D.,Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Taiwan University Hospital


Taiwan: Department of Health

Study ID:




Start Date:

October 2009

Completion Date:

June 2011

Related Keywords:

  • Metastatic Breast Cancer
  • Breast Cancer
  • Breast Neoplasms